Xenogeneic antigen presenting cells and uses thereof
Xenogeneic antigen presenting cells from swine are used to treat tumors by inducing a targeted immune response, overcoming limitations of traditional therapies and enhancing cancer immunotherapy efficacy.
WO2026085177A1 Publication Date: 2026-04-23ONCONEX LLC +2
0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/051020
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-16
- Filing Date
- 2025-10-15
- Publication Date
- 2026-04-23
AI Technical Summary
Technical Problem
Traditional cancer therapies, such as chemotherapy and radiation, are inadequate for treating cancer and often associated with severe side effects, while existing cancer immunotherapies do not demonstrate a robust immune response.
Method used
Administering xenogeneic antigen presenting cells derived from swine expressing alpha-1,3 galactosyltransferase to patients via intratumoral injection, which can trigger a specific immune response against tumors, including solid cancers resistant to chemotherapy and immunotherapy.
Benefits of technology
The method induces an effective immune response against tumors, including abscopal effects, and can be administered in combination with other anti-cancer therapies, providing a robust treatment option with reduced side effects.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to methods for treating a tumor in a subject via administering (e.g., by intratumoral injection) a composition comprising antigen presenting cells obtained from a species that is different than the subject, i.e., xenogeneic antigen presenting cells. The source of such xenogeneic antigen presenting cells could be one or more swine (e.g, a swine that expresses alpha- 1,3 galactosyltransferase). The present disclosure also relates to methods of treating tumors via administering the xenogeneic antigen presenting cells in combination with other anti-cancer therapies. Furthermore, the present disclosure relates to pharmaceutical compositions comprising xenogeneic antigen presenting cells.
Need to check novelty before this filing date? Find Prior Art